Monoclonal antibody and Evusheld therapies transition to normal operations

As management of COVID-19 gradually transitions from a crisis response to standard operations, emergency waivers that allowed for temporary care delivery models are expiring and require the development of permanent processes and workflows. As a result, the last day of operation for the dedicated monoclonal antibody (mAb) clinics was Friday, April 8. This change impacts the administration of mAb and Evusheld therapies.

Learn more about how the administration of mAb and Evusheld therapies will be impacted.